E-155 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Epitomics e155
    E155, supplied by Epitomics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/e155/product/Epitomics
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    e155 - by Bioz Stars, 2022-08
    86/100 stars
      Buy from Supplier

    94
    Abcam anti pp2a alpha beta antibody e155
    CIP2A, I2PP2A, and <t>PP2A</t> in neuroblastoma cell lines. (A) Immunoblotting revealed CIP2A, I2PP2A, and PP2A expression in all four neuroblastoma cell lines studied. There were no differences in expression between the MYCN nonamplified SH-EP and the isogenic MYCN amplified WAC2 cells. (B) SK-N-AS and SH-EP neuroblastoma cells ( MYCN nonamplified) were transfected with MYCN overexpression vector and cell lysates examined for I2PP2A and PP2A. MYCN was successfully expressed in both cell lines. Expression of I2PP2A and PP2A was not affected by MYCN overexpression. (C). Neuroblastoma cell lines were treated with siRNA knockdown of I2PP2A. Whole cell lysates revealed knockdown of I2PP2A with no change in PP2A expression. (D) Neuroblastoma cell lines were treated with siRNA knockdown of CIP2A. Whole cell lysates revealed knockdown of CIP2A with no change in PP2A expression. (E) PP2A activity was measured in SK-N-AS cells following siRNA inhibition. Inhibition of I2PP2A, CIP2A, or dual inhibition led to significant increases in PP2A activity.
    Anti Pp2a Alpha Beta Antibody E155, supplied by Abcam, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pp2a alpha beta antibody e155/product/Abcam
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti pp2a alpha beta antibody e155 - by Bioz Stars, 2022-08
    94/100 stars
      Buy from Supplier

    86
    Taconic Biosciences e 15 5
    CIP2A, I2PP2A, and <t>PP2A</t> in neuroblastoma cell lines. (A) Immunoblotting revealed CIP2A, I2PP2A, and PP2A expression in all four neuroblastoma cell lines studied. There were no differences in expression between the MYCN nonamplified SH-EP and the isogenic MYCN amplified WAC2 cells. (B) SK-N-AS and SH-EP neuroblastoma cells ( MYCN nonamplified) were transfected with MYCN overexpression vector and cell lysates examined for I2PP2A and PP2A. MYCN was successfully expressed in both cell lines. Expression of I2PP2A and PP2A was not affected by MYCN overexpression. (C). Neuroblastoma cell lines were treated with siRNA knockdown of I2PP2A. Whole cell lysates revealed knockdown of I2PP2A with no change in PP2A expression. (D) Neuroblastoma cell lines were treated with siRNA knockdown of CIP2A. Whole cell lysates revealed knockdown of CIP2A with no change in PP2A expression. (E) PP2A activity was measured in SK-N-AS cells following siRNA inhibition. Inhibition of I2PP2A, CIP2A, or dual inhibition led to significant increases in PP2A activity.
    E 15 5, supplied by Taconic Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/e 15 5/product/Taconic Biosciences
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    e 15 5 - by Bioz Stars, 2022-08
    86/100 stars
      Buy from Supplier

    Image Search Results


    CIP2A, I2PP2A, and PP2A in neuroblastoma cell lines. (A) Immunoblotting revealed CIP2A, I2PP2A, and PP2A expression in all four neuroblastoma cell lines studied. There were no differences in expression between the MYCN nonamplified SH-EP and the isogenic MYCN amplified WAC2 cells. (B) SK-N-AS and SH-EP neuroblastoma cells ( MYCN nonamplified) were transfected with MYCN overexpression vector and cell lysates examined for I2PP2A and PP2A. MYCN was successfully expressed in both cell lines. Expression of I2PP2A and PP2A was not affected by MYCN overexpression. (C). Neuroblastoma cell lines were treated with siRNA knockdown of I2PP2A. Whole cell lysates revealed knockdown of I2PP2A with no change in PP2A expression. (D) Neuroblastoma cell lines were treated with siRNA knockdown of CIP2A. Whole cell lysates revealed knockdown of CIP2A with no change in PP2A expression. (E) PP2A activity was measured in SK-N-AS cells following siRNA inhibition. Inhibition of I2PP2A, CIP2A, or dual inhibition led to significant increases in PP2A activity.

    Journal: Translational Oncology

    Article Title: Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth

    doi: 10.1016/j.tranon.2018.09.011

    Figure Lengend Snippet: CIP2A, I2PP2A, and PP2A in neuroblastoma cell lines. (A) Immunoblotting revealed CIP2A, I2PP2A, and PP2A expression in all four neuroblastoma cell lines studied. There were no differences in expression between the MYCN nonamplified SH-EP and the isogenic MYCN amplified WAC2 cells. (B) SK-N-AS and SH-EP neuroblastoma cells ( MYCN nonamplified) were transfected with MYCN overexpression vector and cell lysates examined for I2PP2A and PP2A. MYCN was successfully expressed in both cell lines. Expression of I2PP2A and PP2A was not affected by MYCN overexpression. (C). Neuroblastoma cell lines were treated with siRNA knockdown of I2PP2A. Whole cell lysates revealed knockdown of I2PP2A with no change in PP2A expression. (D) Neuroblastoma cell lines were treated with siRNA knockdown of CIP2A. Whole cell lysates revealed knockdown of CIP2A with no change in PP2A expression. (E) PP2A activity was measured in SK-N-AS cells following siRNA inhibition. Inhibition of I2PP2A, CIP2A, or dual inhibition led to significant increases in PP2A activity.

    Article Snippet: Primary antibodies used for Western blotting included the following: anti-I2PP2A (H-120) (sc-25564) from Santa Cruz Biotechnology (Santa Cruz, CA), anti-PP2A (ab32104) and anti-CIP2A (ab99518) from Abcam (Cambridge, MA), anti–total AKT (9272), anti–phospho-AKT (S473; 9271), anti-MYCN (9405), p44/42 MAP Kinase [ERK1/2 (9102)], anti–phospho-p44/42 MAPK [phospho-ERK, T202/T204, (4377)] from Cell Signaling Technology (Danvers, MA), and anti–β-actin from Sigma (A1978, Sigma Aldrich, St. Louis, MO).

    Techniques: Expressing, Amplification, Transfection, Over Expression, Plasmid Preparation, Activity Assay, Inhibition